Virpax Pharmaceuticals expanded its development and commercialization rights for AnQlar ™ through a global licensing agreement

-AnQlar ™ has already shown antiviral activity against influenza and SARS-CoV-2 in three preclinical studies-

-FDA notified Virpax that the company is authorized to file an NDS (New Drug Submission) application with the Office of Over-the-Counter Drugs-

BERWYN, Pennsylvania, March 16, 2022-(BUSINESS WIRE)-Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company that specializes in developing non-addictive drug candidates to manage pain as well as post-traumatic stress disorder (PTSD), central nervous system (CNS) diseases and certain viral diseases, has extended its agreement exclusive license agreement for AnQlar ™ with Nanomerics Ltd., giving Virpax exclusive global development and marketing rights.

Virpax completed the study in vitro, ex Vivo (human mucous cells) and live (rats) to AnQlar, which showed that AnQlar inhibited SARS-CoV-2 and influenza viral replication in animals at higher levels than seen in human nasal passages. No side effects were observed during the study. Studies have also found lower levels of the virus in the brain tissues of animals. Virpax expects to complete the studies granting Investigational New Drug (IND) status in the fourth quarter of fiscal year 2022 and expects to file for OTC drug authorization.

“We would like to thank our partner, Nanomerics, for working with the Company to restructure our original agreement, which expands the rights in North America into a global agreement, and replaces all commercial measures and royalties by of a revenue-sharing agreement. This makes it easier for us to apply for potential over-the-counter (OTC) drug status with the FDA for AnQlar, ”said Christopher M. Chipman, Chief Financial Officer and Corporate Secretary of Virpax.

“The acquisition of global rights to AnQlar is consistent with our international business model and puts the company in a better position to enter into strategic alliances or pursue commercial opportunities for this drug candidate, “commented Anthony P. Mack. , CEO of Virpax.

About AnQlar ™

AnQlar (GCPQ) is a positively charged chitosan derivative that binds to the electrostatic charge of negatively charged viruses, such as SARS-CoV-2 and influenza. AnQlar can inhibit coronavirus binding to the ACE-2 membrane receptor mediating viral infection. This molecule can have two modes of action: it has virucidal properties and prevents the penetration of the virus into cells through the ACE-2 receptor.

AnQlar is a mucoadhesive polymer with an extended nasal retention time. Applying AnQlar to the nasal mucosa can create a barrier against viral infection by preventing virus binding. Preliminary data obtained in vitro, ex Vivo at live AnQlar has been shown that AnQlar inhibits the replication of SARS-CoV-2 and can prevent viral proliferation as well as viral load in the brain.

About Nanomerics

Nanomerics Ltd is a specialty pharmaceutical company based in London, UK. The nanomerics originated at University College London (UCL) and were created to commercialize its biocompatible polymers for drug delivery and other applications. Nanomerics ’proprietary technology is based on world-class know-how and world-class scientific leadership in polymer nanotechnology. Nanomerics creates unique patented pharmaceutical products, based on quality science. For example, the Molecular Envelope Technology (MET) developed by the company is a unique patented biocompatible polymer that alters bioavailability in target tissue. Nanomerics ’TEM won first prize in the Royal Society of Chemistry’s Emerging Technologies competition. The founders, Prof. Ijeoma F. Uchegbu and Prof. Andreas G. Schätzlein, developed this technology at the universities of Strathclyde and Glasgow, then at UCL’s pharmacy faculty. For more information, visit www.nanomerics.com.

About Virpax Pharmaceuticals

Virpax develops drug candidates for the non-addictive management of pain and neurological diseases, based on its proprietary technologies, to optimize and target drug delivery. Virpax is first seeking FDA approval for its three patented drug delivery platforms. Epoladerm ™ is a film-forming topical formulation of diclofenac spray, developed for the management of osteoarthritis pain. Probudur ™ is a single-injection, long-acting liposomal bupivacaine formulation developed for post-operative pain management. Envelta ™ is an enkephalin formulation using intranasal Molecular Envelope Technology (MET) developed for pain management, specifically in oncology, as well as for the management of post-traumatic stress disorder (PTSD), under the name PES200. MET technology is also used in AnQlar ™, a drug candidate aimed at preventing the replication of influenza viruses or SARS-CoV-2. Virpax recently acquired the worldwide rights to VRP324, a drug candidate for nasal delivery of a cannabidiol (CBD) sold in pharmacies for the management of epilepsy in children (a rare pediatric disease) and adults. For more information, visit www.virpaxpharma.com.

Forward statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, some of which are related to the Company’s clinical plan. tests, product development, clinical and regulatory timelines, market opportunities, competitive position, possible or perceived future operational results, business strategies, potential growth opportunities and other statements with natural prediction. These future statements are based on current expectations, estimates, forecasts and representations about the industry and markets in which we operate, and the opinions and assumptions of management.

These statements are distinguished by the use of forward terms such as, but not limited to, “expect”, “expected”, “aim”, “expected”, “believed”, “estimate”, “potential” , “guess”, “project”, “should”, as well as turns of conditional and similar expressions or their negative forms. These statements relate to future events or to our financial performance, and involve known and unknown risks, uncertainties and other factors, including the potential impact of the COVID- pandemic. 19 as well as social distance efforts. period, in operations, Company projects. and clinical development schedules, which may cause material discrepancies between the results, performance or achievements obtained, and the future results, presentations and achievements indicated or implied in the statements that ito. These factors include those set out in Company reports filed with the Securities and Exchange Commission. Potential investors are warned not to place undue reliance on these statements, which speak only as of the date of this statement. The Company disclaims any obligation to publicly update any future statements, whether as a result of new information or the occurrence of future or other events.

The text of the press release resulting from a translation should not be considered official. The only true version of the press release is the press release in its original language. The translation always has to be compared to the source text, which will set a precedent.

Check out the source version at businesswire.com: https://www.businesswire.com/news/home/20220315005254/en/

contacts

Christopher M. Chipman, Chartered Accountant
Director of finance
cchipman@virpaxpharma.com
610-727-4597

Investor relations:
Betsy Brod
Affinity Growth Advisors
betsy.brod@affinitygrowth.com
212-661-2231

hurry up:
Laura Radocaj
DGI
212-825-3210

Leave a Comment